We hereby attaching you the Board meeting outcome.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Oxygenta Pharmaceutical Ltd announced that Virupaksha Organics Limited has successfully completed the open offer and taken control of the company as the new promoter, effective June 20, 2025. Following this change of control, the board was entirely reconstituted: six new directors were appointed (two executive, one non-executive, and three independent), while six existing directors (three executive and three independent) tendered their resignations. Mr. Sai Sudhakar Vankineni continues as Managing Director & CFO. Most new appointees bring 13–31 years of pharmaceutical and banking experience, though only Mr. Chandra Mouliswar Reddy Gangavaram holds shares in the company (12,895 shares). The company is now referred to as a subsidiary of Virupaksha Organics Limited.
This marks a full change of promoter and management control at Oxygenta Pharmaceutical. Shareholders should expect the new Virupaksha Organics-led board to drive future strategic decisions; in the short term, volatility is possible as the market digests the leadership change and any subsequent business direction announcements.